| 
			
		 | 
		  
			 
		 | 
		  
			
	
		| 
			
				
					Home 
				
			
		 | 
	 
	 
		
			
				
					  - 
						Welcome to the web
						supplement to the
						paper published in the
						"The
						American Journal of
						Pathology, Volume 165,
						pages 107-113":
						
The novel
						marker, DOG1, is
						expressed ubiquitously
						in GI Stromal Tumors
						irrespective of KIT or
						PDGFA mutation
						status. 
					 
- 
Abstract:
 
Accurate diagnosis of gastrointestinal stromal tumors (GISTs) has
				gained increasing importance since
				imatinib mesylate, an inhibitor of the
				KIT tyrosine kinase, was found to
				reduce tumor growth.  Currently, the
				diagnosis of GISTs relies heavily on
				KIT (CD117) immunoreactivity.
				However, KIT- negative GISTs have been
				reported and some of these tumors have
				been shown to harbor a mutation in the
				PDGFRA gene.  We recently
				characterized gene expression patterns
				in GISTs using cDNA microarrays, and
				found that the gene FLJ10261, encoding
				a hypothetical protein, was highly
				expressed in GISTs, compared to other
				mesenchymal tumors.  Synthetic
				peptides based on the gene sequence,
				which we call DOG1, were used to
				generate a rabbit antiserum.  The
				immunoreactivity of this antiserum was
				assessed on two soft tissue tumor
				microarrays (TMAs). The first TMA
				included duplicate cores of 460 soft
				tissue tumors, including 22
				KIT-immunoreactive GISTs.  The second
				TMA included 127 GIST cases for which
				the KIT and PDGFRA mutation status was
				known. 136 of 139 (97.8%) of scorable
				GISTs on these two arrays demonstrated
				immunoreactivity with DOG1 antisera.
				The immunohistochemistry results were
				confirmed by in situ hybridization for
				DOG1, KIT and PDGFRA. Other neoplasms
				in the differential diagnosis of GIST,
				including desmoid fibromatosis (0/17)
				and Schwannoma (0/3), were
				immunonegative for DOG1.  Only four
				non-GIST cases, including two from the
				abdomen, were immunoreactive for DOG1,
				with one of these also reacting for
				KIT.  All 7 GIST cases with a PDGFRA
				mutation were DOG1 positive, while
				most of these failed to react for KIT.
				In addition, 4 of 5 scorable PDGFRA
				mutants were also positive by PDGFRA
				in situ hybridization.  Two
				DOG1-positive, KIT-negative GISTs on
				the first TMA were observed to be
				PDGFRA positive by in situ
				hybridization and subsequently found
				to harbor mutations in exon 18 of
				PDGFRA.  Digital images of over 4,000
				immunostains and in situ
				hybridizations are available at the
				accompanying website.  DOG1, a
				protein of unknown function, is
				expressed strongly on the cell surface
				of GISTs and is rarely expressed in
				other soft tissue tumors.  Use of
				antisera against DOG1 may aid in the
				diagnosis of GISTs, including those
				that fail to express KIT
				antigen.  
				    |     
		 |